P599: Short- and long-term outcome of minimally invasive approach for Crohn’s disease: Comparison between single incision, robotic-assisted and conventional laparoscopyECCO '18 Vienna
2018
P600: Clinical utility of anti-IFI16 seroreactivity in the response to anti-TNF therapy in IBDECCO '18 Vienna
2018
P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST studyECCO '18 Vienna
2018
P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
2018
P603: Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel diseaseECCO '18 Vienna
2018
P605: Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international databaseECCO '18 Vienna
2018
P606: Health-related utility weights in Crohn's disease patients with perianal fistulaECCO '18 Vienna
2018
P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapyECCO '18 Vienna
2018
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumabECCO '18 Vienna
2018
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre studyECCO '18 Vienna
2018
P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort studyECCO '18 Vienna
2018
P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experienceECCO '18 Vienna
2018